UPDATE - Auriga Downgraded HCA Holdings (HCA) to Hold; Macro Issues Moderate, But Still Present Over Next 12 Months
Get Alerts HCA Hot Sheet
Price: $311.03 -0.91%
Rating Summary:
26 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Rating Summary:
26 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
UPDATE - Auriga downgraded HCA Holdings (NYSE: HCA) from Buy to Hold, maintains target of $28.00.
Auriga analyst said, "In a nutshell we believe the macro issues HCA and the other hospital companies have faced have moderated but not disappeared and will remain on the table over the next 12 months. These issues include softness in higher acuity and elective surgeries, reimbursement overhang from Washington and private payors, potential impact from doc fix, and a continued but slow economic recovery. Given the recent run up in HCA, and what we see as a lack of near-term catalysts, we believe the risk/reward profile is not as compelling."
To see more ratings on HCA, Click Here
Auriga analyst said, "In a nutshell we believe the macro issues HCA and the other hospital companies have faced have moderated but not disappeared and will remain on the table over the next 12 months. These issues include softness in higher acuity and elective surgeries, reimbursement overhang from Washington and private payors, potential impact from doc fix, and a continued but slow economic recovery. Given the recent run up in HCA, and what we see as a lack of near-term catalysts, we believe the risk/reward profile is not as compelling."
To see more ratings on HCA, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Arch Coal (ARCH) to Neutral
- OTR Global Downgrades Capri Holdings (CPRI) to Mixed
- Goldman Sachs Downgrades Mitsubishi Estate Co., Ltd. (8802:JP) (MITEY) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!